Manufacture of Third-Generation Lentivirus for Preclinical Use, with Process Development Considerations for Translation to Good Manufacturing Practice
Lentiviral vectors are used in laboratories around the world for in vivo and ex vivo delivery of gene therapies, and increasingly clinical investigation as well as preclinical applications. The third-generation lentiviral vector system has many advantages, ...
Abstract Lentiviral vectors are used in laboratories around the world for in vivo and ex vivo delivery of gene therapies, and increasingly clinical investigation as well as preclinical applications. The third-generation lentiviral vector system has many advantages, including high packaging capacity, stable gene expression in both dividing and post-mitotic cells, and low immunogenicity in the recipient organism. Yet, the manufacture of these vectors is challenging, especially at high titers required for direct use in vivo, and further challenges are presented by the process of translating…
related reading
- Introduction to AAV as a Gene Therapy Vector, Part 2substack.com
- Addgene: Lentiviral Vector Guideaddgene.org
- Lentiviral expression system for the purification of secreted proteins from human cell cultures | BMC Biotechnology | Springer Nature Linkbmcbiotechnol.biomedcentral.com
- Clinical use of lentiviral vectors | Leukemianature.com
- Viral vector platforms within the gene therapy landscape | Signal Transduction and Targeted Therapynature.com
- Introduction to AAV as a Gene Therapy Vector, Part 1substack.com
- CRISPR Gene Therapy: Applications, Limitations, and Implications for the Futurencbi.nlm.nih.gov
- wizardrytakarabio.com
- CG-dinucleotide suppression enables antiviral defense targeting non-self RNA - PMCncbi.nlm.nih.gov
- Making Vaccine — LessWronglesswrong.com
- How to Secure the DNA Supply Chain | IFPifp.org
- RNA Interference–Based Therapy and Its Delivery Systemsncbi.nlm.nih.gov